Butterfly Network, Inc. BFLY

Butterfly Network, Inc. (BFLY) surged 22% to $9.93 on heavy volume after Needham initiated coverage with a Buy rating. The rally was helped by upbeat sentiment around Butterfly Embedded’s multi-year licensing agreement with Merge Labs. The stock has fallen about 9.1% over the past four weeks, but expectations for the next quarter include a loss of $0.03 per share (up 76.9% year over year) on revenue of $28.09 million, up 30.7% from a year ago. Earnings revisions have remained unchanged over the last 30 days, suggesting limited near-term upside unless revisions move higher. Butterfly Network remains a Zacks Rank #3 (Hold) in the Medical Information Systems industry, with peers such as iRhythm Holdings showing mixed recent moves. Needham Buy initiation and Butterfly Embedded licensing deal could lift sentiment and near-term trading, but flat EPS revisions cap upside.

Butterfly Network shares jumped about 22% to close at $9.93 after Needham initiated coverage with a Buy rating and a $10 target, highlighting its differentiated cMUT technology and potential to unlock new medical markets via an embedded business model. The move comes as earlier this month Butterfly inked a multi-year exclusive ultrasound-on-chip deal with Merge Labs, backed by Sam Altman, including upfront and milestone payments, hardware commitments, and ongoing royalties on future sales. Licensing and chip-supply revenues are expected to lift gross margins, echoing a Midjourney partnership that produced $10.8 million in revenue and margins near 71%. Hedge funds increased their Butterfly holdings in Q2, with total position value rising to about $425 million, underscoring elevated sentiment from large investors. Needham's Buy rating with a $10 target and the Merge Labs exclusive ultrasound-on-chip deal plus licensing revenues could meaningfully alter Butterfly Network's revenue mix and margins.

Sam Altman-backed Merge Labs selected Butterfly Network chips for brain interfaces, signaling potential major growth opportunity for BFLY. Chip selection by Merge Labs for brain interfaces opens high-potential new market for BFLY technology.

Merge Labs partners with Butterfly Network to advance ultrasound-based brain-computer interfaces. Partnership targets development of ultrasound brain-computer interfaces with potential to expand Butterfly's core technology applications and market position.

Butterfly Network's Q2 earnings call highlighted embedded growth and prompted a raised company outlook. Raised outlook after Q2 results signals stronger growth trajectory and improved investor sentiment for Butterfly Network.

Butterfly Network held its Q2 2026 earnings call, covering financial results, operational updates, and forward guidance for the company. Quarterly earnings call provides performance details and outlook that may moderately influence short-term market views without major structural shifts.

Butterfly Network reported earnings and raised guidance, leaving a 1% fair value gap. Earnings results combined with raised guidance produce moderately noticeable effects on near-term stock trajectory and sentiment.

Butterfly Network reported Q2 financial results, operational metrics and strategic plans during its earnings call. Quarterly earnings updates deliver financial and operational details that moderately shape near-term investor sentiment.

Butterfly Network raised 2026 outlook citing embedded segment strength, sending shares up 23.4%. Raised 2026 outlook signals stronger future revenue growth and segment performance.

Butterfly Network CEO Joe DeVivo attributes the company's 39% annual growth to key operational and market factors. CEO disclosure of growth drivers signals moderate influence on company trajectory and investor views.

Butterfly Network Inc (BFLY) reported record revenue and surging growth in its Q2 2026 earnings call. Record revenue and growth metrics signal strong performance likely to boost market position and investor sentiment.

Butterfly Network, Inc. (BFLY) reported its second quarter 2026 financial results. Quarterly financial results directly shape investor views and near-term stock movement for Butterfly Network.

Butterfly Network, Inc. summarized its Q2 2026 earnings call, covering quarterly financial results, operational updates and forward guidance. Quarterly earnings releases and guidance directly shape near-term financial outlook and investor positioning.

Butterfly Network held its Q2 2026 earnings call, covering financial results, operational updates and future outlook. Earnings call delivers financial results and guidance that moderately influence near-term stock sentiment and operations view.

Butterfly Network, Inc. posted a Q2 loss while beating revenue estimates. Quarterly earnings results shape near-term investor views on financial performance.

Butterfly Network Inc (BFLY) faces questions whether AI momentum and embedded growth can improve its Q2 results. AI momentum discussion points to moderate influence on BFLY quarterly performance and sentiment.

Butterfly Network filing analyzed against $121 million guidance amid 260% stock surge. Filing review tied directly to major guidance and sharp valuation shift signals notable strategic and investor implications.

Butterfly Network launches handheld ultrasound devices in Brazil. Brazil market entry expands Butterfly Network device sales reach with moderate revenue and positioning effects.

Butterfly Network launches handheld ultrasound devices in Brazil. Brazil launch expands addressable market and supports revenue growth.

Butterfly Network's embedded partner announces breakthrough in brain imaging technology. Partner breakthrough in brain imaging directly strengthens BFLY core tech and competitive edge.

Butterfly Network expands handheld ultrasound availability into Brazil. Brazil market entry adds incremental international revenue potential without transforming core operations or competitive position.

Butterfly Network, Inc. (BFLY) issued comments on Midjourney’s ultrasound scanner announcement. BFLY response to rival ultrasound scanner launch may shift competitive positioning and near-term sentiment.

Butterfly Network’s Embedded partner Aleph Neuro has unveiled striking brain images captured with the technology. Partner product demonstration may generate modest visibility and adoption interest for Butterfly Network technology.

Butterfly Network stock surges after Michael Burry signals approval and Midjourney integrates its ultrasound technology into an AI-powered full-body scanner. Midjourney adoption of Butterfly tech plus Burry endorsement triggers sharp stock rise and signals expanded commercial reach.

Butterfly Network (BFLY) shares surged 55.9% on recent developments, leaving open the question of additional upside potential. BFLY's 55.9% stock surge reflects meaningful market reaction to events that can influence near-term performance and sentiment.

Butterfly Network shares rose after Midjourney unveiled an imaging platform built on the company's Ultrasound-on-Chip technology. Midjourney's platform launch using Butterfly's core technology validates the product and signals expanded commercial applications.

Butterfly Network stock reaches a four-year high on reported ties to AI startup Midjourney. Link to Midjourney raises possibility of new AI features in Butterfly ultrasound devices that could lift near-term sentiment and product positioning.

Butterfly Network Inc. changes board composition with new member Neubauer whose medtech background gains focus for company leadership. Neubauer medtech expertise on Butterfly Network board may moderately shape strategy and market perception.

Butterfly Network, Inc. (BFLY) reported Q1 EPS results. Q1 EPS disclosure represents a major financial event capable of significantly swaying investor sentiment and stock trajectory.

Butterfly Network, Inc. released Q1 2026 earnings call summary detailing financial results, operational updates, and future outlook. Q1 2026 earnings highlights major financial performance and strategic guidance likely to significantly sway BFLY's market trajectory and investor confidence.